Results 31 to 40 of about 1,422,405 (264)

Early Impact of Childhood Opportunity on Neurocognitive Outcomes in Sickle Cell Disease

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Neurocognitive impairment is a well‐recognized complication of sickle cell disease (SCD) that begins early in childhood and persists across development. While cerebrovascular injury contributes substantially to risk, neurocognitive deficits are also observed in children without overt or silent cerebral infarctions, suggesting ...
Julia E. LaMotte   +5 more
wiley   +1 more source

Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange

open access: yesResearch and Practice in Thrombosis and Haemostasis
Background: International Society on Thrombosis and Haemostasis guidelines for immune-mediated thrombotic thrombocytopenic purpura (iTTP) treatment recommend concurrent therapeutic plasma exchange (TPE), immunosuppressive therapy (IST), and caplacizumab.
Brendy Van Butsel   +6 more
doaj   +1 more source

Re‐Irradiation in Pediatric Diffuse Midline Glioma: A Multi‐Institutional Retrospective Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with recurrent diffuse midline gliomas (DMGs) have limited therapeutic options at recurrence. Re‐irradiation (RT2) may be used at progression, but with uncertainty about the benefit. Methods We conducted a multi‐institutional retrospective study of children aged < 18 with DMG treated at three centers (Toronto, Canada ...
Ajay Thomas Alex   +13 more
wiley   +1 more source

Biological assays with special reference to biological standards [PDF]

open access: yesJournal of Hygiene, 1950
A paper on biological assays and biological standards might be expected to start with a definition. What is a biological assay and what is a biological standard? However, I shall for the moment make the somewhat doubtful assumption that we all know the answer to those questions but shall return to them later, making a start meanwhile by discussing some
openaire   +2 more sources

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko   +19 more
wiley   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol   +6 more
wiley   +1 more source

Biological assay of glucagon in rabbits [PDF]

open access: yesDiabetologia, 1969
Bioassay of glucagon based on the hyper-glycaemic activity was investigated in normal rabbits. — It was shown that the index of precision (λ) derived from the dose response curve is about 1.2, which means that several hundred animals are required per assay in order to obtain a reasonably narrow confidence interval. Triple cross-over design improved the
F, Tarding   +3 more
openaire   +2 more sources

BMT4me En Español: Multisite Feasibility and Usability Testing of a Spanish‐Language mHealth Adherence Support App for Spanish‐Speaking Caregivers of Children After Hematopoietic Stem Cell Transplantation and Cancer Treatment

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Medication nonadherence during the first 100 days after pediatric hematopoietic stem cell transplantation (HSCT) and during oncology treatment increases risk for complications. BMT4me is a caregiver‐facing mobile health (mHealth) application providing medication reminders, symptom tracking, and note‐taking features to support ...
Micah A. Skeens   +4 more
wiley   +1 more source

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survival after relapse in pediatric acute myeloid leukemia (AML) remains poor, highlighting the critical importance of identifying prognostic factors to guide optimal relapse management. Methods We investigated the prognostic impact of multiparameter flow cytometry (MFC) measurable residual disease (MRD) in 188 patients with first ...
Camilla Poulsen   +21 more
wiley   +1 more source

Determination of Protein Concentration Using Bradford Microplate Protein Quantification Assay [PDF]

open access: yesDisease and Diagnosis, 2015
Background: Bradford protein assay is popular due to its ease of performance and relative sensitivity. Many researchers and laboratories in Iran use standard assay of Bradford by cuvette.
Rouhollah Valipour Nouroozi   +2 more
doaj  

Home - About - Disclaimer - Privacy